SCHEMBL18987409

SCHEMBL18987409

CCCCCC(C)(C(=O)O)C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GGPS1 O95749 1/20 0.38
EPHX1 P07099 2/20 0.37
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.36
TSHR P16473 4/20 0.36
ALOX15 P16050 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
ACAT1 P24752 1/20 0.36
SOAT1 P35610 1/20 0.36
CES2 O00748 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8654541 0.89 MEN1 (0.37) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL4581998 0.89 MEN1 (0.37) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL599715 0.89 MEN1 (0.37) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL487136 0.88 MAPT (0.46) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL21054110 0.86 CES2 (0.41) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL29690472 0.86 MEN1 (0.40) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL31746162 0.86 DGAT1 (0.35) HSD17B10TSHRCYP3A4CA1CA2
SCHEMBL31627153 0.86 DGAT1 (0.35) HSD17B10TSHRCYP3A4CA1CA2
Potassium SCHEMBL29455954 0.85 MAPT (0.44) MEN1KMT2AMAPTATML3MBTL1
SCHEMBL11362555 0.84 EPHX1 (0.37) MEN1KMT2AMAPTATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228535-A1 SMALL MOLECULES AGAINST CANCER BIOKINE THERAPEUTICS LTD. (IL) 2021-07-29 US disclosed
US-10959979-B2 Small molecules against cancer BIOKINE THERAPEUTICS LTD. (IL) 2021-03-30 US disclosed
US-20200268709-A1 SMALL MOLECULES AGAINST CANCER BIOKINE THERAPEUTICS LTD. (IL) 2020-08-27 US disclosed
US-10646465-B2 Small molecules against cancer BIOKINE THERAPEUTICS LTD. (IL) 2020-05-12 US disclosed
US-20190240188-A1 SMALL MOLECULES AGAINST CANCER ALONBIO LTD. (IL) 2019-08-08 US disclosed
EP-3390378-A1 SMALL MOLECULES AGAINST CANCER Biokine Therapeutics Ltd. (IL) 2018-10-24 EP disclosed
WO-2017103931-A1 SMALL MOLECULES AGAINST CANCER BIOKINE THERAPEUTICS LTD. (IL) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10959979-B2 Small molecules against cancer CCL2, CXCR2, CCL5 MEN1 2693/4885KMT2A 3459/4885MAPT 4157/4885
US-20210228535-A1 SMALL MOLECULES AGAINST CANCER CCL2, CXCR2, CCL5 MEN1 2693/4885KMT2A 3459/4885MAPT 4157/4885
US-10646465-B2 Small molecules against cancer CCL2, CXCR2, CCL5 MEN1 2693/4885KMT2A 3459/4885MAPT 4157/4885
US-20200268709-A1 SMALL MOLECULES AGAINST CANCER CCL2, CXCR2, CCL5 MEN1 2693/4885KMT2A 3459/4885MAPT 4157/4885
US-20190240188-A1 SMALL MOLECULES AGAINST CANCER CCL2, CXCR2, CCL5 MEN1 2693/4885KMT2A 3459/4885MAPT 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.